31 maj: Neurosearch/Nordea: Sænker anbefaling til "sælg"
31 maj: Råvarer: Sydeuropæiske problemer får investorer til at sælge ud
31-05-2012 08:16:00

Prudential PLC Prudential Acquisition -2-

Relateret indhold

This release may contain 'forward-looking statements' with respect to certain of Prudential's plans and its goals and expectations relating to its future financial condition, performance, results, strategy and objectives. Statements that are not historical facts, including statements about Prudential's beliefs and expectations, are forward-looking statements. These statements are based on plans, estimates and projections as at the time they are made, and therefore undue reliance should not be placed on them. By their nature, all forward-looking statements involve risk and uncertainty. A number of important factors could cause Prudential's actual future financial condition or performance or other indicated results to differ materially from those indicated in any forward-looking statement. Such factors include, but are not limited to, future market conditions, fluctuations in interest rates and exchange rates, and the performance of financial markets generally; the policies and actions of regulatory authorities, including, for example, new government initiatives related to the financial crisis and the effect of the European Union's 'Solvency II' requirements on Prudential's capital maintenance requirements; the impact of competition, inflation, and deflation; experience in particular with regard to mortality and morbidity trends, lapse rates and policy renewal rates; the timing, impact and other uncertainties of future acquisitions or combinations within relevant industries; the impact of changes in capital, solvency standards or accounting standards, and tax and other legislation and regulations in the jurisdictions in which Prudential and its affiliates operate; and the impact of legal actions and disputes. These and other important factors may for example result in changes to assumptions used for determining results of operations or re-estimations of reserves for future policy benefits. Further discussion of these and other important factors that could cause Prudential's actual future financial condition or performance or other indicated results to differ, possibly materially, from those anticipated in Prudential's forward-looking statements can be found under the 'Risk factors' heading in the Annual Report and the 'Risk Factors' heading of Prudential's most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission, as well as under the 'Risk Factors' heading of any subsequent Prudential Half Year Financial Report. Prudential's most recent Annual Report, Form 20-F and any subsequent Half Year Financial Report are/will be available on its website at www.prudential.co.uk.

Any forward-looking statements contained in this document speak only as of the date on which they are made. Prudential expressly disclaims any obligation to update the forward-looking statements contained in this document or any other forward-looking statements it may make, whether as a result of future events, new information or otherwise except as required pursuant to the UK Prospectus Rules, the UK Listing Rules, the UK Disclosure and Transparency Rules, the Hong Kong Listing Rules, the SGX-ST listing rules or other applicable laws and regulations.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACQGSGDUCBXBGDB

(END) Dow Jones Newswires

May 31, 2012 02:16 ET (06:16 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Novo/ATP: Succes afhænger også af de mindste forretningsben

23-03-2017 15:28:28
Hvis Novo Nordisk skal forblive succesfuld i den kommende årti, så er det ikke nok, at Novo styrker sin førerposition på diabetesmarkedet. Novos forretning inden for fedme og hæmofili må også styrkes, mener ATP, der derfor benyttede taletiden på generalforsamlingen til at spørge ind til Novos syn på opkøb.- Efter min mening er det nødvendigt, at Novo Nordisk supplerer sin interne forskning og udvi..

Novo/CEO: Vi skal stadig fokusere på produktfornyelse

23-03-2017 14:34:32
Novo Nordisk har stærke produkter, men står samtidig over for store udfordringer i USA, hvor sygekasserne presser på for at sænke priserne.Det erkender administrerende direktør Lars Fruergaard Jørgensen på torsdagens generalforsamling.- På den ene side har Novo Nordisk med en meget stærk produktportefølje, men på den anden side står vi også over for et meget stærkt pres på vores forretning i USA, ..

Aktier/åbning: Mærsk skyder til tops i C20 efter Nordsøaftale

23-03-2017 09:18:19
Investorerne er glade for A.P. Møller-Mærsk-aktierne torsdag morgen, hvor det er gjort klart, at Thyra-feltet vil blive genopbygget efter en aftale om olie- og gasproduktion i Nordsøen.Mærsks A-aktie stiger med 0,5 pct. til 11.120 kr., og B-aktien stiger med 0,3 pct. til 11.540 kr.- Det er ret væsentligt for Maersk Oil, at det her kommer i hus, for ambitionen om selvstændighed og om at fokusere si..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo/aktionærer: Tingene kører ikke længere af sig selv
2
Vestas/Barclays: De store kan klemme de små i vindbranchen
3
Parken får bøde og Don Ø idømmes fængsel i halvandet år - NY2
4
Pandora vil uddele optioner for op til 77 mio. kr.
5
Novo/ATP: Succes afhænger også af de mindste forretningsben

Relaterede aktiekurser

Prudential PLC ORD 5P 1.719,85 0,0% Aktiekurs uændret
Prudential Public Limite.. 43,02 0,0% Aktiekurs uændret
Prudential USD 9,4000 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. marts 2017 07:09:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170322.1 - EUROWEB1 - 2017-03-24 07:09:43 - 2017-03-24 07:09:43 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x